Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis

Bibliography

• Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009;8:663-7
   PubMed Web of Science ®Google Scholar
• Soubrier M, Barber-Chamoux N, Tatar Z, et al. Cardiovascular risk in rheumatoid arthritis. Joint Bone Spine 2014;81:298-302
   PubMed Web of Science ®Google Scholar
• Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7
   PubMed Web of Science ®Google Scholar
• Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010;69:1920-5
   PubMed Web of Science ®Google Scholar
• Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7
   PubMed Web of Science ®Google Scholar
• Liao K, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 2013;52:45-52
   PubMed Web of Science ®Google Scholar
• Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9
   PubMed Web of Science ®Google Scholar
• Giles JT, Ling SM, Ferrucci L, et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 2008;59:807-15
   PubMed Web of Science ®Google Scholar
• Westhovens R, Nijs J, Taelman V, et al. Body composition in rheumatoid arthritis. Br J Rheumatol 1997;36:444-8
   PubMedGoogle Scholar
• Sattar N, McCarey DW, Capell H, et al. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63
   PubMed Web of Science ®Google Scholar
• Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2005;2:113-21
   PubMedGoogle Scholar
• Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008;9:1121-8
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Eng J Med 2005;352:1685-95
   PubMed Web of Science ®Google Scholar
• Boyer JF, Gourraud PA, Cantagrel A, et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011;78:179-83
   PubMed Web of Science ®Google Scholar
• Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004;43:1219-23
   PubMed Web of Science ®Google Scholar
• Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, et al. Obesity in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:450-62
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Gremese E. Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Med Wkly 2011;141:w13211
   PubMed Web of Science ®Google Scholar
• Dao HH, Do QT, Sakamoto J. Abnormal body composition phenotypes in Vietnamese women with early rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1250-8
   PubMed Web of Science ®Google Scholar
• Toussirot E, Grandclément B, Gaugler B, et al. Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study. Front Immunol 2013;4:453
   Web of Science ®Google Scholar
• Kaul S, Rothney MP, Peters DM, et al. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring) 2012;20:1313-18
   PubMed Web of Science ®Google Scholar
• Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012;126:1301-13
   PubMed Web of Science ®Google Scholar
• Giles JT, Bartlett SJ, Andersen R, et al. Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum 2008;58:2632-41
   PubMed Web of Science ®Google Scholar
• Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Phase III) final report. Circulation 2005;106:3143-421
   Google Scholar
• Crowson CS, Myasoedova E, Davis JM, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 2011;38:29-35
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32
   PubMed Web of Science ®Google Scholar
• Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007;66:958-61
   PubMed Web of Science ®Google Scholar
• Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66:1503-7
   PubMed Web of Science ®Google Scholar
• Popa C, Arts E, Fransen J, et al. Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biological. Mediators Inflamm 2012;2012:785946
   PubMed Web of Science ®Google Scholar
• Daïen CI, Duny Y, Barnetche T, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012;71:862-8
   PubMed Web of Science ®Google Scholar
• van Sijl AM, Peters MJ, Knol DL, et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2011;41:393-400
   PubMed Web of Science ®Google Scholar
• Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use is associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011;63:530-4
   PubMed Web of Science ®Google Scholar
• Voloshyna I, Seshadri S, Anwar K, et al. Infliximab reverses suppression of cholesterol efflux proteins by TNFalpha: a possible mechanism for modulation of atherogenesis. Biomed Res Int 2014;2014:312647
   Web of Science ®Google Scholar
• Engvall IL, Tengstrand B, Brismar K, et al. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 2010;12:R197
   PubMed Web of Science ®Google Scholar
• Serelis J, Kontogianni MD, Katsiougiannis S, et al. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol 2008;27:795-7
   PubMed Web of Science ®Google Scholar
• Metsios GS, Strapollos-Kalinoglou A, Douglas KM, et al. Blockade of tumour necrosis factor – a in rheumatoid arthritis : effects on components of rheumatoid cachexia. Rheumatology 2007;46:1824-7
   PubMed Web of Science ®Google Scholar
• Toussirot E, Mourot L, Dehecq B, et al. TNFalpha blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. Eur J Nutr 2014;53:951-61
   PubMed Web of Science ®Google Scholar
• Hmamouchi I, Roux C, Paternotte S, et al. Early increase of abdominal adiposity in patients with spondyloarthritis receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2014;41:1112-17
   PubMed Web of Science ®Google Scholar
• Marcora SM, Chester KR, Mittal G, et al. Randomised phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006;84:463-72
   Google Scholar
• Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-8
   PubMed Web of Science ®Google Scholar
• Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012;14:R141
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6
   PubMed Web of Science ®Google Scholar
• Hürlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7
   PubMed Web of Science ®Google Scholar
• Irace C, Mancuso G, Fiaschi E, et al. Effect of anti TNF alpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004;177:113-18
   PubMed Web of Science ®Google Scholar
• Mäki-Petäjä KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-92
   PubMed Web of Science ®Google Scholar
• Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1428-32
   PubMed Web of Science ®Google Scholar
• Del Porto F, Laganà B, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1111-15
   PubMed Web of Science ®Google Scholar
• Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, et al. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006;55:150-3
   PubMed Web of Science ®Google Scholar
• Mathieu S, Couderc M, Pereira B, et al. The effects of TNF-alpha inhibitor therapy on arterial stiffness and endothelial dysfunction in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2013;43:e1-2
   PubMedGoogle Scholar
• Marks JL, Edwards CJ. Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Ther Adv Musculoskelet Dis 2012;4:149-57
   Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
   PubMed Web of Science ®Google Scholar
• Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522-9
   PubMed Web of Science ®Google Scholar
• Ljung L, Askling J, Rantapää-Dahlqvist S, et al. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014;16:R127
   PubMed Web of Science ®Google Scholar
• Desai RJ, RAo JK, Hansen RA, et al. Tumor necrosis factor-alpha inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis : a nested case –control study. J Rheumatol 2014;41:2129-36
   PubMed Web of Science ®Google Scholar
• Dixon WG, Symmons DP. What effects might anti-TNF alpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007;66:1132-6
   PubMed Web of Science ®Google Scholar
• Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31
   PubMed Web of Science ®Google Scholar
• Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, et al. Rheumatoid arthritis, cardiovascular disease and physical exercise : a systematic review. Rheumatology(Oxford) 2008;47:239-48
   PubMed Web of Science ®Google Scholar
• Reiss AB, Carson SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transportation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008;58:3675-83
   PubMed Web of Science ®Google Scholar
• Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207
   PubMed Web of Science ®Google Scholar
• Meune C, Touzé E, Trinquart L, et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009;48:1309-13
   PubMed Web of Science ®Google Scholar
• Norton S, Nikiphorou E, Carpenter L, et al. Reduced mortality risk in rheumatoid arthritis: findings from two UK inception cohorts. Arhritis Rheumatol 2014;66(Suppl):S1226-7
   Google Scholar